NASDAQ:LIFE aTyr Pharma (LIFE) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free life Stock Alerts $1.57 -0.02 (-1.26%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$1.57▼$1.6150-Day Range$1.57▼$2.0252-Week Range$1.08▼$2.70Volume239,955 shsAverage Volume321,232 shsMarket Capitalization$106.67 millionP/E RatioN/ADividend YieldN/APrice Target$23.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get aTyr Pharma alerts: Email Address aTyr Pharma MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside1,407.4% Upside$23.67 Price TargetShort InterestHealthy0.56% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.54Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.97) to ($1.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.74 out of 5 starsMedical Sector412th out of 913 stocksBiological Products, Except Diagnostic Industry65th out of 154 stocks 3.4 Analyst's Opinion Consensus RatingaTyr Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageaTyr Pharma has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.56% of the outstanding shares of aTyr Pharma have been sold short.Short Interest Ratio / Days to CoveraTyr Pharma has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in aTyr Pharma has recently decreased by 12.31%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldaTyr Pharma does not currently pay a dividend.Dividend GrowthaTyr Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LIFE. Previous Next 3.1 News and Social Media Coverage News SentimentaTyr Pharma has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for aTyr Pharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for LIFE on MarketBeat in the last 30 days. This is a decrease of -87% compared to the previous 30 days.MarketBeat Follows4 people have added aTyr Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, aTyr Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of aTyr Pharma is held by insiders.Percentage Held by Institutions61.72% of the stock of aTyr Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for aTyr Pharma are expected to decrease in the coming year, from ($0.97) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of aTyr Pharma is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of aTyr Pharma is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioaTyr Pharma has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About aTyr Pharma Stock (NASDAQ:LIFE)aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.Read More LIFE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LIFE Stock News HeadlinesApril 27, 2024 | americanbankingnews.comAnalyzing aTyr Pharma (NASDAQ:LIFE) & Fennec Pharmaceuticals (NASDAQ:FENC)April 25, 2024 | americanbankingnews.comaTyr Pharma (NASDAQ:LIFE) Stock Passes Above 200-Day Moving Average of $1.54April 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 21, 2024 | finance.yahoo.comaTyr Pharma Insiders Placed Bullish Bets Worth US$514.6kApril 17, 2024 | msn.comAtal Incubation Centre - Centre for Cellular and Molecular Biology signs agreement with Thermo Fisher Scientific to advance innovation in IndiaApril 17, 2024 | americanbankingnews.comaTyr Pharma (NASDAQ:LIFE) Stock Price Crosses Above 200 Day Moving Average of $1.54April 1, 2024 | finance.yahoo.comaTyr Pharma to Participate in April Investor ConferencesApril 1, 2024 | globenewswire.comaTyr Pharma to Participate in April Investor ConferencesApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 26, 2024 | investorplace.com3 Penny Stocks That Could Be Multibaggers in the Making: March EditionMarch 18, 2024 | msn.com3 Best Stocks to Buy Now, 3/18/2024, According to Top AnalystsMarch 17, 2024 | finanznachrichten.deaTyr Pharma, Inc.: aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate UpdateMarch 16, 2024 | benzinga.comRecap: aTyr Pharma Q4 EarningsMarch 16, 2024 | finance.yahoo.comaTyr Pharma Full Year 2023 Earnings: Revenues DisappointMarch 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for aTyr Pharma as Lead Candidate efzofitimod Advances in Clinical Trials with Solid Financial FootingMarch 15, 2024 | finance.yahoo.comaTyr Pharma Inc (LIFE) Reports Full Year 2023 Financial Results and Corporate ProgressMarch 15, 2024 | finance.yahoo.comQ4 2023 aTyr Pharma Inc Earnings CallMarch 15, 2024 | finance.yahoo.comaTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | investorplace.comLIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023March 14, 2024 | washingtonpost.comAtyr Pharma: Q4 Earnings SnapshotMarch 14, 2024 | globenewswire.comaTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate UpdateMarch 14, 2024 | msn.comOptions Volatility and Implied Earnings Moves Today, March 14, 2024March 13, 2024 | benzinga.comaTyr Pharma's Earnings OutlookMarch 13, 2024 | markets.businessinsider.comaTyr Pharma is about to announce earnings — here's what Wall Street expectsFebruary 28, 2024 | globenewswire.comaTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial ResultsFebruary 23, 2024 | finance.yahoo.comWe Think aTyr Pharma (NASDAQ:LIFE) Can Afford To Drive Business GrowthFebruary 21, 2024 | finance.yahoo.comaTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial ParticipantsSee More Headlines Receive LIFE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/27/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:LIFE CUSIP53217V10 CIK1339970 Webwww.atyrpharma.com Phone(858) 731-8389Fax858-731-8394Employees56Year Founded2005Price Target and Rating Average Stock Price Target$23.67 High Stock Price Target$35.00 Low Stock Price Target$16.00 Potential Upside/Downside+1,407.4%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,390,000.00 Net MarginsN/A Pretax Margin-14,276.77% Return on Equity-49.84% Return on Assets-39.12% Debt Debt-to-Equity Ratio0.02 Current Ratio6.27 Quick Ratio6.27 Sales & Book Value Annual Sales$350,000.00 Price / Sales304.76 Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / Book1.02Miscellaneous Outstanding Shares67,940,000Free Float65,427,000Market Cap$106.67 million OptionableOptionable Beta1.25 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Sanjay S. Shukla M.D. (Age 52)M.S., President, CEO & Director Comp: $768.18kMs. Jill M. Broadfoot (Age 62)Chief Financial Officer Comp: $544.75kMs. Nancy E. Denyes Krueger (Age 56)General Counsel & Corporate Secretary Comp: $518.2kXiang-Lei Yang Ph.D.FounderMs. Ashlee DunstonDirector of Investor Relations & Corporate CommunicationsMr. Peter VilligerVice President of Corporate DevelopmentMs. Danielle CampbellVP of Human ResourceDr. Leslie Nangle Ph.D.Vice President of ResearchDr. Ying J. Buechler Ph.D.Executive Director of Biologics Development & ManufacturingDr. David J. King Ph.D. (Age 65)Scientific Consultant Comp: $327.31kMore ExecutivesKey CompetitorsBioAtlaNASDAQ:BCABOutlook TherapeuticsNASDAQ:OTLKbluebird bioNASDAQ:BLUEVigil NeuroscienceNASDAQ:VIGLCardiol TherapeuticsNASDAQ:CRDLView All CompetitorsInsiders & InstitutionsKingswood Wealth Advisors LLCBought 60,000 shares on 4/15/2024Ownership: 0.088%Pale Fire Capital SEBought 237,849 shares on 2/14/2024Ownership: 0.502%Stonepine Capital Management LLCSold 4,144,366 shares on 2/13/2024Ownership: 0.824%Granite Bay Wealth Management LLCBought 18,000 shares on 1/29/2024Ownership: 0.031%Sanjay ShuklaBought 3,000 shares on 12/11/2023Total: $3,510.00 ($1.17/share)View All Insider TransactionsView All Institutional Transactions LIFE Stock Analysis - Frequently Asked Questions Should I buy or sell aTyr Pharma stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LIFE shares. View LIFE analyst ratings or view top-rated stocks. What is aTyr Pharma's stock price target for 2024? 4 brokers have issued 12 month price targets for aTyr Pharma's shares. Their LIFE share price targets range from $16.00 to $35.00. On average, they predict the company's stock price to reach $23.67 in the next year. This suggests a possible upside of 1,407.4% from the stock's current price. View analysts price targets for LIFE or view top-rated stocks among Wall Street analysts. How have LIFE shares performed in 2024? aTyr Pharma's stock was trading at $1.41 on January 1st, 2024. Since then, LIFE shares have increased by 11.3% and is now trading at $1.57. View the best growth stocks for 2024 here. Are investors shorting aTyr Pharma? aTyr Pharma saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 436,900 shares, an increase of 51.0% from the March 15th total of 289,300 shares. Based on an average daily volume of 540,800 shares, the days-to-cover ratio is presently 0.8 days. View aTyr Pharma's Short Interest. When is aTyr Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our LIFE earnings forecast. How were aTyr Pharma's earnings last quarter? aTyr Pharma, Inc. (NASDAQ:LIFE) announced its quarterly earnings data on Thursday, March, 14th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.02. When did aTyr Pharma's stock split? aTyr Pharma's stock reverse split on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is Sanjay Shukla, M.D, M.S's approval rating as aTyr Pharma's CEO? 3 employees have rated aTyr Pharma Chief Executive Officer Sanjay Shukla, M.D, M.S on Glassdoor.com. Sanjay Shukla, M.D, M.S has an approval rating of 100% among the company's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of aTyr Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX). When did aTyr Pharma IPO? aTyr Pharma (LIFE) raised $76 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers. Who are aTyr Pharma's major shareholders? aTyr Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Kingswood Wealth Advisors LLC (0.09%). Insiders that own company stock include Jill Marie Broadfoot, John K Clarke, Paul Schimmel and Sanjay Shukla. View institutional ownership trends. How do I buy shares of aTyr Pharma? Shares of LIFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LIFE) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsProtect Your Bank Account Before It’s Too LateWeiss RatingsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThey say it’s ‘unstoppable’ – How I made 43,509% Investing Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.